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Abstract 
Sclerosing mesenteritis is associated with a spectrum of diseases which include 
mesenteric lipodystrophy and mesenteric panniculitis. This inflammatory and fibrosing 
disorder can affect the small and large bowel wall and mesenteric vessels by exerting a 
mass effect. The following case highlights the difficulties with diagnosing and managing 
this unusual disease. A 64-year-old man presented with acute central abdominal pain, 
radiating to his back, and profuse vomiting. He was diagnosed clinically with small bowel 
obstruction. He had had an episode of small bowel obstruction 6 years earlier. At this 
time, he underwent an exploratory laparotomy, and a mass was identified in the small 
bowel mesentery. The features were thought to be in keeping with sclerosing 
mesenteritis. He had a dramatically favourable response to the initiation of prednisolone. 
He continued to be well and asymptomatic for a further 5 years on long-term 
maintenance low-dose steroids and 6-mercaptopurine. He re-presented in 2009 (six years 
after initial presentation) with very severe acute abdominal pain and vomiting. He had 
no recent change in weight or appetite, and had not had time off work. He underwent a 
second laparotomy and the tissue diagnosis was of metastatic carcinoid tumour 
involving the small bowel mesentery. This is the first case to our knowledge where 
sclerosing mesenteritis has been confirmed histologically on biopsy and then 
subsequently diagnosed with histologically proven carcinoid tumour. For this particular 
reason it must be always remembered that sclerosing mesenteritis is a ‘pathological’ and 
not a radiological diagnosis and that a large proportion of cases are associated with 
neoplasia. 
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Introduction 
Sclerosing mesenteritis is associated with a spectrum of diseases which include 
mesenteric lipodystrophy and mesenteric panniculitis. This inflammatory and fibrosing 
disorder can affect the small and large bowel wall and mesenteric vessels by exerting a 
mass effect. The first known series, which comprised 34 cases of ‘retractile mesenteritis 
and mesenteric sclerosis’, was published in 1924 [1]. This disorder is relatively 
uncommon and predominantly affects men aged between 50 and 70 years. There are a 
variety of symptoms associated with this disorder which include nausea, vomiting, weight 
loss and fever [2–4]. In 1997 after a review of 84 cases, Emory et al. [5] concluded that 
these histological variants are part of one disease process and that sclerosing mesenteritis 
would be an appropriate common term. Due to the low incidence of this condition it has 
been difficult to study the clinical features, natural history, and ultimate response to 
therapy and prognosis. Many of the therapeutic regimes to treat sclerosing mesenteritis 
have been guided by anecdotal evidence and small case series [6–9]. 
The pathophysiology of sclerosing mesenteritis remains obscure, although there have 
been several proposed mechanisms. These include abdominal surgery or trauma [5], 
autoimmunity [10–13], paraneoplastic syndrome [2, 3, 5, 14], ischaemic injury and 
infection [15]. The following case highlights the difficulties with diagnosing, managing 
and appropriate follow-up for this unusual disease. 
Case Report 
A 64-year-old man presented in 2009 with acute central abdominal pain, radiating to his back, and 
profuse vomiting. He had no recent change in weight or appetite and had not had time off work. In late 
2008 he had also presented with two discrete acute episodes of small bowel obstruction. Both of these 
episodes responded rapidly to pulsed high-dose corticosteroids. His symptoms dated back to 2003 when 
he had presented with abdominal pain, weight loss and vomiting. At this time, he was diagnosed 
clinically with small bowel obstruction. At that stage he had a CT abdominal scan which diagnosed a 
‘small bowel mass’. The working diagnosis was small bowel lymphoma. He subsequently underwent an 
exploratory laparotomy. A mass was identified in the small bowel mesentery, this was biopsied and an 
adjacent lymph node was dissected. In 2003 the biopsy specimen was reported as follows: ‘… there is 
evidence of an infiltrative process, with entrapment of lymph nodes, nerves, blood vessels and fat. The 
process involves fibrosis, lymphocyte infiltration, focal fat necrosis and eosinophilic infiltration.’ There 
was no evidence of lymphoma in the tissue or lymph node specimens. These pathological features were 
thought to be in keeping with sclerosing mesenteritis. This was confirmed by two experienced 
gastrointestinal pathologists. He had a dramatically favourable response to the initiation of prednisolone 
and was started on 6-mercaptopurine (as a steroid-sparing agent) and did not complain of any further 
abdominal pain or lethargy. He remained well and asymptomatic for a further 5 years on long-term 
maintenance low-dose steroids and 6-mercaptopurine. 
From his most recent admission in April 2009 a CT abdomen was performed which demonstrated ‘a 
soft tissue mass measuring 22 × 30 mm, “spiculated” in appearance and anterior to the third part of the 
duodenum. Small bowel loops appeared to encircle and were adherent to the soft tissue density and 
there were dilated proximal small bowel loops. There was a 9 mm low density lesion in segment 3 of the 
liver’ (fig. 1). The differential diagnosis was sclerosing mesenteritis with adhesions or carcinoid tumour 
(with a desmoplastic reaction). He had a second laparotomy which confirmed the soft tissue mass 
adherent to the mid small bowel and a mesenteric mass. A nodule was identified and biopsied from the 
left lobe of the liver. The biopsy results revealed cells in a ‘nested appearance’ that stained positively for 
AE1/AE3, chromogranin and synaptophysin, consistent with a diagnosis of carcinoid. There was also 
carcinoid tumour present in the resected node and liver nodule. Therefore the diagnosis was metastatic 
carcinoid tumour. He subsequently had normal urinary 5-HIAA and neuroendocrine markers and did 
not report any symptoms of the carcinoid syndrome. Subsequent pathological review and repeat 
staining of the biopsy taken in 2003 did not reveal any evidence of carcinoid disease.  
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Discussion 
Sclerosing mesenteritis has been previously associated with other co-existent 
conditions including lymphoma, breast cancer, melanoma, bronchial carcinoma, renal 
carcinoma, multiple myeloma, hepatocellular carcinoma, prostate carcinoma, ovarian 
carcinoma, and gastrointestinal carcinomas [3, 14, 16]. In the literature there has been 
confusion when radiological imaging ‘mistakenly’ clinically and radiologically diagnosed 
sclerosing mesenteritis, when in fact the underlying diagnosis was carcinoid disease after 
histological confirmation. 
This is the first case to our knowledge where sclerosing mesenteritis has been 
confirmed histologically on biopsy and subsequently diagnosed as histologically proven 
carcinoid tumour. What makes this case particularly interesting is that this patient had a 
dramatic response to steroids. Steroid responsiveness does not tend to be a feature of 
carcinoid tumours where the mainstay of therapy is octeotride [17, 18] and occasionally 
interferon-alpha [19–22] for refractory symptoms, but steroid responsiveness is 
consistent with sclerosing mesenteritis. Steroids have been shown to be beneficial in the 
treatment of sclerosing mesenteritis [6, 7, 9]. This patient had no symptoms to suggest 
features of the carcinoid syndrome, which is often the case in metastatic carcinoid 
disease – in fact more than 90% of cases of carcinoid syndrome will have the disease. 
For this particular reason it must be always remembered that sclerosing mesenteritis is 
a ‘pathological’ and not a radiological diagnosis. Therefore when diagnosing sclerosing 
mesenteritis a clinician must have a high index of suspicion for other serious co-existent 
conditions, especially neoplasia. 
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Fig. 1. Abdominal CT demonstrating the ‘spiculated’ soft tissue mass in the upper small bowel anterior 
to the third part of the duodenum (yellow arrow). The dilated proximal small bowel segment is 
indicated by the red arrows. Note that the colon is collapsed due to a proximal obstruction. 
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